Trials / Completed
CompletedNCT00719680
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 2 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IgPro20 |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2008-07-22
- Last updated
- 2014-04-02
- Results posted
- 2013-01-25
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00719680. Inclusion in this directory is not an endorsement.